Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.
The immune system fights cancer and sometimes temporarily eliminates it or reaches an equilibrium stage of tumor growth. However, continuous immunological pressure also selects poorly immunogenic tumor variants that eventually escape the immune control system. Here, we focus on metastatic melanoma, a highly immunogenic tumor, and on anti-melanoma immunotherapies, which recently, especially following the FDA approval of Ipilimumab, gained interest from drug development companies. We describe new immunomodulatory approaches currently in the development pipeline, focus on the novel CEACAM1 immune checkpoint, and compare its potential to the extensively described targets, CTLA4 and PD1. This paper combines multi-disciplinary approaches and describes anti-melanoma immunotherapies from molecular, medical, and business angles.
Ella Institute for Melanoma, Sheba Medical Center, Ramat Gan 52621, Israel.
Sivan
S
Sapoznik
Ohad
O
Hammer
Rona
R
Ortenberg
Michal J
MJ
Besser
Tehila
T
Ben-Moshe
Jacob
J
Schachter
Gal
G
Markel
D019264:Adoptive Transfer; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000191:economics / Q000379:methods*; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology*
D000911:Antibodies, Monoclonal